StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$6.70−0.43 (-6.03%)

Close on Nov 18, 2026Market cap $359.32MP/E –Yield –

Avalo Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Avalo Therapeutics's revenue for the twelve months ending Dec 31, 2025 was $59.00K, down 86.6% year over year. For fiscal 2025 it was $59.00K, down 86.6% from the year before. The highest annual figure on record is $27.81M in fiscal 2017.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$59.00K-86.6%
FY2024Dec 31, 2024$441.00K-77.1%
FY2023Dec 31, 2023$1.92M-89.3%
FY2022Dec 31, 2022$18.05M+234.4%
FY2021Dec 31, 2021$5.40M-19.4%
FY2020Dec 31, 2020$6.70M-0.8%
FY2019Dec 31, 2019$6.75M-4.0%
FY2018Dec 31, 2018$7.03M-74.7%
FY2017Dec 31, 2017$27.81M+2312.3%
FY2016Dec 31, 2016$1.15M–
FY2015Dec 31, 2015$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$59.00K–
Q3 FY2025Sep 30, 2025$0–
Q4 FY2024Dec 31, 2024$192.00K-66.4%
Q3 FY2024Sep 30, 2024$249.00K+5.5%
Q2 FY2024Jun 30, 2024$0-100.0%
Q1 FY2024Mar 31, 2024$0-100.0%
Q4 FY2023Dec 31, 2023$571.00K-36.3%
Q3 FY2023Sep 30, 2023$236.00K-98.4%
Q2 FY2023Jun 30, 2023$643.00K-37.8%
Q1 FY2023Mar 31, 2023$475.00K-59.5%
Q4 FY2022Dec 31, 2022$896.00K+309.1%
Q3 FY2022Sep 30, 2022$14.95M+1007.3%
Q2 FY2022Jun 30, 2022$1.03M-69.2%
Q1 FY2022Mar 31, 2022$1.17M+148.0%
Q4 FY2021Dec 31, 2021$219.00K-85.4%
Q3 FY2021Sep 30, 2021$1.35M+21.5%
Q2 FY2021Jun 30, 2021$3.36M+150.7%
Q1 FY2021Mar 31, 2021$473.00K-82.8%
Q4 FY2020Dec 31, 2020$1.50M+157.7%
Q3 FY2020Sep 30, 2020$1.11M-49.5%
Q2 FY2020Jun 30, 2020$1.34M-3.9%
Q1 FY2020Mar 31, 2020$2.75M+6.9%
Q4 FY2019Dec 31, 2019$580.81K-88.3%
Q3 FY2019Sep 30, 2019$2.20M-46.0%
Q2 FY2019Jun 30, 2019$1.39M-70.9%
Q1 FY2019Mar 31, 2019$2.58M-42.5%
Q4 FY2018Dec 31, 2018$4.98M+160.8%
Q3 FY2018Sep 30, 2018$4.07M-83.7%
Q2 FY2018Jun 30, 2018$4.79M+2932.4%
Q1 FY2018Mar 31, 2018$4.48M+1066.8%
Q4 FY2017Dec 31, 2017$1.91M+955.8%
Q3 FY2017Sep 30, 2017$25.04M+7687.8%
Q2 FY2017Jun 30, 2017$157.80K–
Q1 FY2017Mar 31, 2017$384.21K–
Q4 FY2016Dec 31, 2016$181.00K–
Q3 FY2016Sep 30, 2016$321.50K–

More Avalo Therapeutics figures

See a number that looks wrong?